Resultados: 29

    Grading of recommendations, assessment, development, and evaluation (GRADE): Novavax COVID-19 vaccine

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...

    ACIP evidence to recommendations for use of Novavax COVID-19 vaccine, adjuvanted in adults ages 18 years and older under an emergency use authorization

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), in late 2019 has led to a global pandemic with dramatic societal and economic impact on individual persons and communities. In the United States, more than 89 million cases and more than 1 million COVID-19-associated ...

    Directrices para el tratamiento de las leishmaniasis en la región de las américas - 2 ed

    Las leishmaniasis son enfermedades infecciosas desatendidas de gran importancia en la Región de las Américas debido a su morbilidad, mortalidad y amplia distribución geográfica. De las tres formas clínicas principales, la cutánea es la más común y la visceral es la forma más grave, ya que puede ...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Moderna COVID-19 vaccine for children aged 6 months–5 years

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for children aged 6 months­-­­5 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 18,...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Pfizer-BioNTech COVID-19 vaccine for children aged 6 months-4 Years

    Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine for children aged 6 months­–­­4 years was presented to the Advisory Committee for Immunization Practices (ACIP) on ...

    The Moderna COVID-19 vaccine’s local reactions, systemic reactions, adverse events, and serious adverse events

    Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. The frequency of local reactions was higher in the older age group (ages 2 to 5 years) than the younger ag...

    ACIP update to the evidence to recommendations for a Pfizer-BioNTech COVID-19 booster in children ages 5-11 years

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 82 million cases and more than 998,000 COVID-19-associated deaths have...

    ACIP update to the evidence to recommendations for a 2nd COVID-19 booster dose in adults ages 50 years and older and immunocompromised Individuals

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 80 million cases and more than 986,000 COVID-19-associated deaths have...

    ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2 [Pré-print]

    The present guideline has the objective of identifying the most appropriate diagnostic test and/or diagnostic/screening approach for1) patients with signs and symptoms of COVID-19; 2) travelers from areas with low and high COVID-19 prevalence, healthcare workers, and other individuals at risk for exposur...

    Prevención de la transmisión maternoinfantil del virus de la hepatitis B. directrices sobre la profilaxis con antivirales en el embarazo

    Según estimaciones de la Organización Mundial de la Salud (OMS), en el 2015 257 millones de personas en el mundo tenían la infección crónica por el virus de la hepatitis B (VHB) y 900 000 fallecieron a causa de ella, en la mayor parte de los casos de cirrosis o carcinoma hepatocelular. La mayoría d...